SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions

20130115165 - Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric: Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropylacrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral; either water-soluble vinyl derivatives like vinylpryolidone (VP) or vinyl acetate (VA), or... Agent:

20130115166 - Anti-il-23 heterodimer specific antibodies: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components... Agent: Cephalon Australia Pty Ltd.

20130115167 - Peptides that home to atherosclerotic plaques and methods of use: The invention provides methods of targeting atherosclerotic plaques using LyP-1 related peptides. The invention additionally provides methods of treating an inflammatory condition using LyP-1 related peptides.... Agent: Sanford-burnham Medical Research Institute

20130115168 - Catalytic radiofluorination: One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to arylammonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the ammonium... Agent: The General Hospital Corporation

20130115170 - Gm1-like peptides and uses thereof: Compositions and methods relating to interfering with the interaction of gangliosides, such as GM1, with their ligands are provided. For example, methods are provided for treating infections by blocking the infectious agent from binding with GM1 using GM1-like peptides. Also provided are methods of inhibiting ligands from binding to GM... Agent:

20130115169 - Red blood cell-mimetic particles and methods for making use thereof: The present technology provides synthesized particles that mimic key structural and functional features of red blood cells. Such RBC-mimicking particles possess the ability to carry oxygen (and carbon dioxide) and flow through capillaries smaller than their own diameter. Further, such particles can also deliver drugs and imaging agents. These particles... Agent: The Regents Of The University Of Michigan

20130115171 - Nav1.7-related assays: A viable global NaV1.7−/− knockout mouse is disclosed, and a breeding colony of global NaV1.7−/− knockout mice. Also disclosed are an isolated mouse gamete that does not encode a functional NaV1.7, produced by the NaV1.7−/− knockout mouse; an isolated NaV1.7−/− mouse cell, or a progeny cell thereof, isolated from the... Agent:

20130115172 - Magnetic nanophosphor having core/shell structure and the synthetic method thereof: v

20130115173 - Stable dermatological aerosol foams utilizing reactive propellants: Described herein are chemically-stabile formulations comprising a reactive propellant. The formulations are delivered as an aerosol foam, and are suitable for topical application. The aerosol propellant may be a hydrofluoroolefin propellant. The emulsions or compositions may comprise reactive active agents, such as peroxides, retinoids, or quinones. Also described are methods... Agent: Precision Dermatology, Inc.

20130115174 - Transmucosal composition containing anthocyanins for alleviating a visual discomfort: The present invention relates to a composition comprising a natural extract containing anthocyanins and an agent for enhancing vigilance, and to a method for alleviating visual discomfort related to or caused by oxidative stress comprising administering via transmucosal route the composition of the invention, said composition being in a form... Agent:

20130115175 - Periodontal bacterial growth inhibitor, oral hygiene product, and food and drink: A periodontal bacterial growth inhibitor contains as an active ingredient a Macaranga tanarius extract extracted from Macaranga tanarius with an extraction solvent including at least an organic solvent. Alternatively, the periodontal bacterial growth inhibitor contains as an active ingredient at least one selected from nymphaeol-A, nymphaeol-B, and nymphaeol-C. The periodontal... Agent: Pokka Corporation

20130115176 - Materials for dissolution-controlled release: A controlled release substance containing organosilica sol-gels is provided. The organosilica sol-gels may be further functionalized with amino groups to control the rate of release of encapsulated molecules. The controlled release substance may be utilized as a controlled release fabric care substance, including at least one active fabric care substance... Agent: Board Of Trustees At Southern Illinois University

20130115178 - Tanning enhancers and self-tanning substances: The invention relates to the use of alduronic acids and dialdehydes of the aldoses and derivatives thereof as tanning enhancers for dihydroxyacetone or for a mixture of self-tanning substances comprising dihydroxyacetone or as self-tanning substance. The invention furthermore relates to the use thereof for modulation of the hue achieved in... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20130115177 - Topical compositions and methods for epithelial-related conditions: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions... Agent: Signum Biosciences, Inc.

20130115180 - Methods and compositions for administering a specific wavelength phototherapy: Methods and compositions are disclosed for administering electromagnetic radiation (EMR), for therapeutic or cosmetic purposes, or for purposes of curing a polymeric material.... Agent:

20130115179 - Novel compounds: The invention relates to novel polyglycerol based UV-filters as well as to topical compositions comprising such novel polyglycerol based UV-filters. Furthermore, the invention relates to the use of such novel polyglycerol based UV-filters to enhance the solubility of butyl methoxydibenzoylmethane or bis-ethylhexyloxyphenol methoxyphenyl triazine in cosmetic oils.... Agent:

20130115181 - Aqueous pharmaceutical system for the administration of drugs to the nails: Aqueous pharmaceutical system for the administration of drugs to the nails. The invention relates to a topical preparation for treating diseases of the toenails and/or hands nails, based on a thermosensitive aqueous gel that at room temperature behaves as a dissolution and after application of nails, forming a hydrated layer,... Agent: Universidade De Santiago De Compostela

20130115183 - Method of preparing hair and scalp conditioning composition including aromatic oil blend with enhanced efficacy: Disclosed is a method of preparing a hair and scalp conditioning composition. According to the method, a hair cosmetic base and aromatic oils are aged by separate reaction processes and are blended to improve the stability of the aromatic oils. Therefore, the activities of the aromatic oils, particularly for the... Agent:

20130115184 - Saccharide siloxanes stable in aqueous environments and methods for the preparation and use of such saccharide siloxanes: A novel saccharide siloxane copolymer has improved stability in the presence of water as compared to certain previously known saccharide siloxanes. The saccharide siloxane copolymer is useful in personal care compositions.... Agent: Dow Corning Corporation

20130115185 - Structured acrylate copolymer thickeners: Disclosed are multi-staged acrylic based core-shell polymers comprising a linear core polymer and at least one subsequently polymerized shell polymers is crosslinked. The core-shell polymers surprisingly provide desirable rheological, clarity, and aesthetic properties in aqueous surfactant containing compositions, particularly at low pH.... Agent: Lubrizol Advanced Materials, Inc.

20130115182 - Topical use of steviol or derivatives in hair care: The present invention relates to the use of steviol and/or isosteviol, or a salt, ester, a diester, or an ether thereof as depicted in formula (I), formula (I): R1 wherein R1 is hydrogen (H) or a saturated, straight or branched C1-C8 alkyl group non substituted or substituted with up to... Agent: Dsm Nutritional Products Ltd.

20130115187 - Biodegradable material containing silicon, for pro-angiogenetic therapy: The present invention relates to a silicon-containing, biodegradable material for preventing and/or treating diseases that are associated with reduced and/or disturbed angiogenesis and/or diseases for which an increased rate of angiogenesis is beneficial to the healing process.... Agent: Bayer Innovation Gmbh

20130115186 - Silicon-containing biodegradable material for anti-inflammatory therapy: The present invention relates to a silicon-containing, biodegradable material for preventing and/or treating diseases that are associated with increased interleukin-1β and/or interleukin-6 and/or interleukin-8 activity and/or that can be treated by lowering said cytokine activity.... Agent: Bayer Innovation Gmbh

20130115188 - Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In... Agent: Immatics Biotechnologies Gmbh

20130115190 - Hepatitis c virus inhibitors: e

20130115193 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Bristol-myers Squibb Company

20130115192 - Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles: This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly(ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization from” approach... Agent: Bind Biosciences, Inc

20130115191 - T cell receptor fusions and conjugates and methods of use thereof: Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and... Agent: Altor Bioscience Corporation

20130115189 - Use of interleukin-1 beta mutein conjugates in the treatment of diabetes: The present invention provides compositions, pharmaceutical compositions and vaccines for the treatment, amelioration and/or prophylaxis of type II diabetes. The compositions, pharmaceutical compositions and vaccines of the invention comprise a virus-like particle of an RNA bacteriophage and an antigen, wherein said antigen comprises an interleukin-1 beta (IL-1β) mutein. When administered... Agent: Cytos Biotechnology Ag

20130115194 - Hepatitis c virus inhibitors: wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing... Agent:

20130115199 - T-cell receptor and nucleic acid encoding the receptor: A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of... Agent: Takara Bio Inc.

20130115195 - Anti-aging formulations: A dietary supplement based on fucoidan, blue-green algae, phycocyanin and phenylethylamine is fortified with one or more of curcumin, silymarin, resveratrol, astragalus root extract, astragoloside IV, vitamin D3, vitamin C, anhydrous trimethylglycine and brewers yeast to stimulate stem cell production and reduce the rate of telomere reduction or shortening. This... Agent:

20130115197 - Amnion-derived cell compositions, methods of making and uses thereof: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived... Agent: Stemnion, Inc.

20130115198 - Hair follicle mesenchymal stem cells and use thereof: The present invention relates to a method for isolating hair follicle mesenchymal stem cells and to the use thereof for therapy and prophylaxis as well as for cosmetic treatments.... Agent: Trichoscience Innovations Inc.

20130115196 - Hybrid hydrogel scaffold compositions and methods of use: The present invention includes new hybrid hydrogel scaffolds comprised of a polyoxyethylene-polyoxypropylene (block) copolymer (a “poloxamer”) and a self-assembling peptide, which maintain the mechanical and bioactive properties of its individual constituents (as compared to when the individual constituents are scaffolds or hydrogels by themselves). The hydrogels of the invention can... Agent: Escape Therapeutics, Inc.

20130115200 - Cell therapy: Dextran sulfate is used in order to reduce pulmonary uptake of intravenously injected Dextran sulfate is capable of reducing the pulmonary uptake of the intravenously injected cells to the levels obtained for intraarterial injection of the cells but without the accompanying risks and side effects of using intraarterial cell injection.... Agent: Tx Medic Ab

20130115202 - Anti-inflammatory compositions for treating neuro-inflammation: This disclosure pertains to methods of treating a neuro-inflammation disorder in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a flavonoid, or a structurally related analogue, olive kernel extract, hydroxytyrosol, and berberine, and, optionally, one or more ingredients selected from the... Agent: Theta Biomedical Consulting & Development Co., Inc

20130115201 - Fluid supplement with prenatal vitamins: A fluid supplement is provided that is specifically tailored to meet the health and nutritional needs of a pregnant woman and her developing fetus. The fluid supplement also combats the symptoms of nausea and vomiting that are commonly associated with pregnancy. The fluid supplement contains vitamins, minerals, dietary supplements, and... Agent:

20130115203 - Enzyme and prebiotic combinations for enhancing probiotic efficacy: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and α-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and β-glucanase. Other combinations of fibers and enzymes are described below which also stimulate... Agent:

20130115204 - Preparative purification process for human furin: Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC™ resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC™ chromatography... Agent: Baxter International Inc.

20130115205 - Cleaning composition with decyl and coco glucosides: A cleansing composition comprising surfactants comprising decyl glucoside and coco glucoside, wherein the decyl glucoside is present in an amount by weight that is 1.5 to 2.5 times the weight of coco glucoside.... Agent: Colgate-palmolive Company

20130115206 - Compositions and methods for treating and diagnosing cancer: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin... Agent: Oncomed Pharmaceuticals, Inc.

20130115208 - Heterodimeric proteins and methods for producing and purifying them: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.... Agent: Rinat Neuroscience Corp.

20130115207 - Methods for the treatment of autoimmune diseases: The invention provides methods of treating a mammal (e.g., a human) having or at risk of having an autoimmune disease by administering a composition that includes all or a portion of a viral polypeptide or a nucleic acid encoding a viral peptide (e.g., a live, killed, attenuated, or inactivated virus)... Agent: The General Hospital Corporation

20130115210 - Peptide for use in the treatment of breast cancer and/or bone metastases: The invention relates to the use of the Peptide of the formula Cyclo-(Arg-Gly-Asp-DPhe-NMe-Val) and/or the pharmaceutically acceptable dervatives, solvates and/or salts thereof, for the manufacture of a medicament for the treatment of breast cancer and/or bone metastases in humans, wherein the medicament is optionally to be used in combination with... Agent: Merck Patent Gmbh

20130115209 - Protective vaccine based on staphylococcus aureus protein sa2412: The present invention relates to methods of inducing an immune response to Staphylococcus comprising administering a composition comprising an SA2412 polypeptide from Staphylococcus aureus as well as derivatives or fragments thereof. The present also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition... Agent:

20130115211 - Cytokine antagonists for neurological and neuropsychiatric disorders: A method, comprising: introducing a therapeutically effective amount of a specific TNF blocker to cerebrospinal fluid of a human in need of treatment for symptoms associated with neronal compression.... Agent:

20130115213 - Human cd3-specific antibody with immunosuppressive properties: Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for the human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith... Agent: Affimed Therapeutics, Ag

20130115212 - Modulation of the interaction between sorla and gdnf-family ligand receptors: The present invention relates to a method to increase the survival of neurons by modulating the interaction between SorLA and GDNF-family ligand receptors. The agent used to modulate the interaction between the SorLA and GDNF-family ligand receptors are selected from proteins, peptides, antibodies or small organic compounds. The invention also... Agent: Lundbeck A/s

20130115215 - Domain insertion immunoglobulin: Described herein is an antibody format, which is amenable to bispecific antibody creation. This format is referred to herein as “Domain Insertion Immunoglobulin G” or “(Di-IgG)”. The Di-IgG molecules are capable of specifically binding two different antigens simultaneously, show high level recombinant expression, and are sufficiently aggregation-free to be amenable... Agent:

20130115214 - Neuropilin antagonists: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.... Agent: Genentech, Inc.

20130115217 - Antibodies against hmgb1 and fragments thereof: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to particular fragments of HMGB1, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade, methods of detecting and/or identifying an agent that binds to an HMGB1 polypeptide... Agent: The Feinstein Institute For Medical Research

20130115218 - Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides: Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated GAD autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of... Agent: Technion Research & Development Foundation Ltd

20130115216 - Survivin-derived peptides and uses thereof: MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-γ-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in... Agent: Survac Aps

20130115219 - Expression vector: The present invention provides an expression vector for cell-surface expression of proteins.... Agent: F. Hoffmann-la Roche Ag

20130115220 - Method for prevention or treatment of metabolic syndrome: The present invention aims to provide a method for the prophylaxis or treatment of metabolic syndrome, which can discontinue the domino effect-like chain of diseases in metabolic syndrome in the upstream by suppressing infiltration of macrophage into the adipose tissues. The present invention provides a method for the prophylaxis or... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20130115223 - Antagonists of pcsk9: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors,... Agent: Merck Sharp & Dohme Corp.

20130115221 - Hifa prolyl hydroxylation assay: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the... Agent: Dana Farber Cancer Institute, Inc.

20130115222 - Methods of limiting microvascular damage following acute myocardial ischemia: This disclosure has identified a new ligand-receptor system, proNGF and p75NTR/SorCS2, which is found to be involved in the microvascular functions of the heart. This disclosure provides methods for limiting microvascular damage following acute myocardial ischemia based on administration of an antagonist of this newly identified system, thereby promoting myocardial... Agent: Cornell University

20130115224 - Methods of treating disorders using human antibodies that bind human tnfalpha: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in... Agent:

20130115227 - Anti-addl monoclonal antibody and uses thereof: Disclosed are antibodies that bind amyloid beta-derived diffusible ligands, also known as ADDLs. The antibodies are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation... Agent:

20130115226 - Methods and uses of tie2 binding and/or activating agents: The present disclosure provides methods and uses of Tie2 binding and/or activating agents. In particular, the present disclosure provides methods and uses for inhibiting the expansion of colony forming unit-granulocytes, reducing eosinophils and/or basophils, for treating allergic disease or response or eosinophil/basophil associated condition and for reducing inflammatory cytokine and/or... Agent: Sunnybrook Health Sciences Centre

20130115225 - Reducer of immunosuppression by tumor cell and antitumor agent using the same: The invention features methods for inhibiting enhancement of expression of a FoxP3 gene in a cell, methods for inhibiting induction of differentiation of a cell into a regulatory T cell, methods for reducing immunosuppression, methods for stimulating tumor immunity, and methods for treating a patient with a tumor. The methods... Agent: Keio University

20130115228 - Immunostimulatory combinations: The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.... Agent: Trustees Of Dartmouth College

20130115229 - Method for detecting malignant tumor cells: Provided is a detection method for a malignant tumor cell, including measuring a protein marker expressed on a malignant tumor cell surface. The detection method for a malignant tumor cell includes measuring LR11 on a cell surface in a sample to be tested.... Agent: Sekisui Medical Co., Ltd.

20130115230 - Delivery proteins: Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of a payload, e.g., an immunogen, to the reticuloendothelial system via non-circulating lymphoid cells are provided.... Agent: Augmenta Biologicals, LLC

20130115231 - Liquid formulation of long-acting human growth hormone conjugate: Disclosed is a liquid formulation of long-acting human growth hormone (hGH) conjugate, free of albumin, which can guarantee the stability of the long-acting hGH conjugate when stored over a long period of time, wherein the long-acting human growth hormone conjugate includes a human growth hormone linked to an immunoglobulin Fc... Agent: Hanmi Science Co., Ltd.

20130115232 - Methods for detecting graft-versus-host disease: The disclosure relates to the development of methods for detecting or predicting graft-versus-host disease (GVHD) and for detecting or predicting response to treatment for GVHD. More particularly, the disclosure provides new biomarkers and combinations of biomarkers for detecting or predicting gastrointestinal GI GVHD and for predicting and analyzing response to... Agent: The Regents Of The University Of Michigan

20130115233 - Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability: The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the modulation of unwanted immune responses, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino... Agent: Declion Pharmaceuticals, Inc.

20130115234 - Ectodomains of influenza matrix 2 protein, expression system, and uses thereof: The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of an influenza viral infection. Provided is an isolated polynucleotide encoding multiple copies of M2 influenza ectodomain peptides or rMVA comprising the polynucleotide. Also provided... Agent: Emergent Product Development Gaithersburg,inc.

20130115236 - Prophylaxis and treatment of prdc: The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs.... Agent: Boehringer Ingelheim Vetmedica, Inc.

20130115235 - Swine influenza hemagglutinin variants: The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... Agent: Medimmune, LLC

20130115238 - Meningococcal fhbp polypeptides: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a... Agent: Novartis Ag

20130115237 - Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment: The present invention generally relates to HIV compositions and methods of use. One aspect of the present invention relates to a composition comprising a pharmaceutically acceptable carrier and an antigen preparation, the antigen preparation comprising an HIV polypeptide or fragment thereof and a Bacillus anthracis lethal factor (LF) polypeptide, such... Agent: Vaccine Technologies, Incorporated

20130115241 - Microvesicles derived from cell protoplast and use thereof: The present application relates to microvesicles derived from a protoplast which is a bacterial, arhaea, fungal or plant cell or the like from which a cell wall is removed. The microvesicles derived from a protoplast enables free loading of a material necessary for diagnosis, treatment, vaccine, target induction, cell membrane... Agent: Aeon Medix Inc.

20130115239 - Prostate cancer dna vaccine: The present invention concerns an (adjuvant) treatment or prevention option for the treatment and prevention of prostate cancer. In particular, it pertains to the provision of recombinant, optimized PAP genes which are useful as DNA vaccines for the above treatment or prevention.... Agent: Universit&#xc4 T Konstanz

20130115240 - Recombinant bcg strains with enhanced ability to inhibit intracellular mycobacterial growth: A recombinant bacterial cell strain is disclosed. It comprises: a) a first vector comprising a fusion transgene encoding Ag85B-CFP10 fusion protein, the fusion transgene being operably linked to a promoter effective for expression of the Ag85B-CFP10 fusion protein; and b) a second vector comprising a transgene encoding interleukin-12 (IL-12), the... Agent: National Health Research Institutes

20130115242 - Modified viral strains and method for improving the production of vaccine seeds of influenza virus: Modified influenza A/PR/8/34 virus and reassortant influenza A/PR/8/34 virus including a modified PB1 gene and methods for improving the production of HA (hemagglutinin) and NA (neuraminidase) vaccine glycoproteins.... Agent: Hospices Civils De Lyon

20130115243 - Immunogenic formulations and their uses: An immunogenic formulation for a patient, the formulation includes virus-modulated hematopoietic cancer cells, where the modulated hematopoietic cancer cells are generated from viable hematopoietic cancer cells obtained from the patient, either isolated or in a mixed hematopoietic population of healthy and cancer cells, and where the viable hematopoietic cancer cells... Agent: Ottawa Hospital Research Institute

20130115244 - Immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic... Agent: Yisheng Biopharma (singapore) Pte. Ltd.

20130115245 - Vaccine for tumor immunotherapy: The present invention relates to a vaccine comprising dendritic cells and bacterial ghosts for tumor immunotherapy.... Agent:

20130115254 - Aptamer-loaded, biocompatible nanoconstructs for nuclear-targeted cancer therapy: Disclosed herein is a nanoconstruct comprising an aptamer and a gold nanostar. The nanoconstruct can be used in a method of inducing changes to a nuclear phenotype of a cell comprising transporting the nanoconstruct to a nucleus of a cell, and releasing the aptamer from a surface of the gold... Agent: Northwestern University

20130115250 - Burst drug release compositions: Solid dose compositions comprising at least one low solubility pharmaceutically active ingredient, at least one low solubility filler and at least one controlled release agent. comprising at least one poorly soluble pharmaceutically active ingredient, a insoluble binder and at least one controlled release agent along with a method of manufacturing... Agent: Wyeth LLC

20130115257 - Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates: Methods and compositions for treating biofilms and diseases associated with amyloidosis such as Alzheimer's, Parkinson's and Huntington's disease, and Type 2 diabetes, by destroying amyloid fibrils in a two-step treatment are disclosed. The first step consists of binding to the amyloid fibril an intercalating molecule with a negatively charged group... Agent: Katholieke Universiteit Leuven

20130115248 - Debridement paste: The present invention relates to a new and inventive composition for implant cleaning and/or debridement of hard surfaces in the oral cavity, which comprises optimally activated nanoparticles of TiO2, having a mean particle diameter (D50) of about 10-100 nm at a concentration between 0.5-500 g/L, and H2O2, at a concentration... Agent: Corticalis As

20130115252 - Genipin-rich material and its use: A method of preparing genipin-rich materials from the fruit of Genipa americana fruit for their use as a cross-linking agent and as a raw material to produce colors is disclosed. The genipin-rich materials can be used in a broad range of applications including personal care, cosmetics, dietary supplements, packaging, textiles,... Agent: Wild Flavors, Inc.

20130115256 - Methods for treating or preventing vascular graft failure: The described invention provides pharmaceutical compositions and methods for treating or preventing vascular graft failure in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent... Agent:

20130115249 - Osmotic device containing amantadine and an osmotic salt: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity... Agent: Osmotica Kereskedelmi Es Szolgaltato Kft

20130115255 - Particulate tissue graft with components of differing density and methods of making and using the same: Disclosed are tissue graft compositions made of particles having different densities, methods of making these compositions, and methods of using these compositions for promoting tissue restoration in a patient.... Agent:

20130115246 - Reduced dose oral pharmaceutical compositions of fenofibrate: The invention relates to reduced dose oral pharmaceutical composition of fenofibrate which exhibits substantial bioequivalence to Antara® Capsules under fasting condition and also capable of reducing the food effect on bioavailability of fenofibrate. Provided is a pharmaceutical composition comprising about 90 mg of fenofibrate particles having a D90 particle size... Agent: Lupin Atlantis Holdings, S.a.

20130115253 - Sustained release suspension preparation for dextromethorphan: A stabilized pharmaceutical composition comprises a drug-resin complex wherein the resin has been treated with an alkaline material prior to the formation of the drug-resin complex. The drug-resin complex may further be impregnated with an alkalizing agent, L-methionine, an antioxidant agent, or a combination thereof, or be coated with a... Agent:

20130115251 - Tandem facial amphiphiles: The invention provides tandem facial amphiphiles for biochemical manipulations and characterization of membrane proteins, such as intrinsic membrane proteins. Members of this new family display favorable behavior with several membrane proteins. These amphiphiles can form relatively small micelles, and small changes in amphiphile chemical structures can result in large changes... Agent: Wisconsin Alumni Research Foundation

20130115247 - Virion derived protein nanoparticles for delivering radioisotopes for the diagnosis and treatment of malignant and systemic disease and the monitoring of therapy: The invention is directed to novel compositions and methods utilizing virion derived protein nanoparticles for delivery of medical imaging agents and therapeutic agents for the diagnosis and treatment of malignant and systemic diseases.... Agent: Aura Biosciences, Inc.

20130115258 - Emulsion: The invention relates to the encapsulation of oxidisable lipids. In particular, the invention provides an oil-in-water emulsion comprising droplets of a core lipid coated with nanoemulsion droplets, wherein the nanoemulsion droplets comprise a surface lipid coated with protein. The emulsions of the invention provide an oxidatively stable form of the... Agent: Massey University

20130115259 - Polymeric systems for delivering hypohalide salts: The invention relates to polymeric systems for stabilizing, storing and delivering hypohalide salts. One system consists of material coated with two layers: one prepared from polyethylene glycol epoxide and melamine solution and second prepared from inorganic hypohalide salt solution. The material can be fabric, cotton, bamboo, cellulosic materials, blend of... Agent: The University Of South Dakota

20130115260 - Antimicrobial composition: An antimicrobial composition containing coniferous resin acids and/or their derivates, an antimicrobial polymer composition including coniferous resin acids and/or their derivates and processes for preparing thereof, and the use of the derivates of coniferous resin acids as an antimicrobial agent.... Agent: Taiga Polymers Oy

20130115261 - Use of formulations having insecticidal activity:

20130115262 - Substrate having an electron donating surface with metal particles comprising palladium on said surface: A substrate with an electron donating surface, characterized in having metal particles on said surface, said metal particles having palladium and at least one metal selected from gold, ruthenium, rhodium, osmium, iridium, or platinum, wherein the amount of said metal particles is from about 0.001 to about 8 μg/cm2. Examples... Agent: Bactiguard Ab

20130115263 - Compositions and methods for coating medical implants: Medical implants are provided which release a fluoropyrimidine or an analog thereof, thereby inhibiting or reducing the incidence of infection associated with the implant.... Agent: Angiotech Pharmaceuticals, Inc.

20130115264 - Implantable rasagiline compositions and methods of treatment thereof: A method of treating the symptoms of Parkinson's disease comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of rasagiline to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a... Agent: Endo Pharmaceuticals Solutions Inc.

20130115265 - Drug delivery system: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a... Agent: Msd Oss B.v.

20130115266 - Edible wafer-type product for delivery of nutraceuticals and pharmaceuticals: A food product for carrying and delivery nutraceutical or pharmaceutical or both is provided. The food product may be an edible wafer-based outer layer and an inner layer of an edible filling comprising the nutraceutical or pharmaceutical or both.... Agent: Bestsweet, Inc.

20130115267 - Compositions and methods for reducing edema: The invention provides compositions and methods for the treatment and/or reversal of an edema, e.g., including a central nervous system (CNS) edema, e.g., a brain or a spinal edema, edema in a burned or an injured tissue such as skin, or any tissue edema. In alternative embodiments, the invention provides... Agent: The Regents Of The University Of California

20130115268 - Methods of administering a dermatological agent to a subject: Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of... Agent: Teikoku Pharma Usa, Inc.

20130115270 - Anti-interleukin-1 (il-1) antibody used as a targeting agent to treat arthritis and other diseases: This invention describes the use of anti-IL-1 antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-IL-1 antibody coated liposomes. The... Agent:

20130115269 - Anti-tumor necrosis factor alpha (tnf-a) antibody used as a targeting agent to treat arthritis and other diseases: This invention describes the use of anti-TNF-a antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-TNF-a coated liposomes. The anti-TNF-a... Agent:

20130115279 - Cd133 epitopes: An immunogen includes an isolated peptide that includes the amino sequence of any one of SEQ ID NOs:1-21 with four or fewer amino acid substitutions.... Agent: Immunocellular Therapeutics, Ltd.

20130115273 - Combinational liposome compositions for cancer therapy: The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.... Agent: Mallinckrodt LLC

20130115274 - Method of producing lipid nanoparticles for drug delivery: What is described is a method for preparing a liposome that efficiently encapsulates a negatively charged therapeutic polymer, e.g., siRNA. The process involves preparing a lipid mixture comprising a cationic lipid in a water miscible organic solvent, such as ethanol, at a concentration of 2.3 mg/ml, and adding this solution... Agent: Nitto Denko Corporation

20130115272 - Modified nucleosides, nucleotides, and nucleic acids, and uses thereof: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.... Agent: Moderna Therapeutics

20130115275 - Peptide epitopes of apolipoprotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent:

20130115276 - Peptide epitopes of apolipoprotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent:

20130115277 - Peptide epitopes of apolipoprotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent:

20130115278 - Peptide epitopes of apolipoprotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent:

20130115271 - Predictors of pharmacokinetic and pharmacodynamic disposition of carrier-mediated agents: The invention provides a method of predicting the clearance rate of a carrier-mediated agent and/or the release of an agent from a carrier in a subject comprising measuring the number and/or activity of phagocytic cells and/or the amount and/or activity of opsonins and/or the amount and/or activity of complement within... Agent: The University Of North Carolina At Chapel Hill

20130115280 - Pharmaceutical and/or dietary compositions based on sort chain fatty acids: Pharmaceutical and/or dietary compositions based on short chain fatty acids or salts, esters and/or amides thereof in combination with one or more dietary soluble or water-dispersible fibre and at least one flavouring agent are disclosed.... Agent: Cosmo Technologies Ltd

20130115281 - Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation: A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form comprising a statin compound and at least one liquid fill phase comprising Omega-3 fatty acids. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid... Agent: Accucaps Industries Limited

20130115282 - Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof: A polymeric matrix for oral administration with modified release and taste masking properties is disclosed, obtained without using inert supports such as sugar spheres, comprising particles of active substance directly and individually covered with a release regulating membrane. Use of such a matrix to prepare various administration forms for oral... Agent: I. P.s. International Products & Services S.r.i.

20130115284 - Omega3 fatty acid compound preparation: Provided is a compound preparation including at least one selected from the group consisting of ω3 polyunsaturated fatty acids and pharmaceutically acceptable salts and esters thereof and at least one selected from the group consisting of statin compounds and pharmaceutically acceptable salts thereof. The compound preparation is in a form... Agent: Mochida Pharmaceutical Co., Ltd.

20130115283 - Solid naproxen concentrates and related dosage forms: The invention provides a composition consisting essentially of a solid naproxen concentrate, wherein the solid naproxen concentrate comprises (a) a solid naproxen free acid and (b) a solid naproxen alkali salt, and wherein at least 90% of the weight of the solid naproxen concentrate is naproxen free acid and naproxen... Agent: Pharmaceutics International, Inc.

20130115285 - Enteric coating compositions and methods of making and using the same: An enteric coating composition including about 0.01% to about 10% resin and about 0.01% to about 10% polymer. The enteric coating composition may be applied to a substrate, such as a pharmaceutical, nutraceutical, fruit, vegetable, agricultural product, or industrial product, to form an enteric coating on the substrate. Also provided... Agent:

20130115286 - Oral administration forms for controlled release of rifampicin for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract: Oral administration forms are described for the controlled release of an antibiotic selected from the group consisting of rifampicin, rifabutin, rifapentine, rifalazil and mixtures thereof, for treating bacterial infections of the gastrointestinal tract, in particular travellers' diarrhoea, hepatic encephalopathy, ulcerative colitis, irritable bowel syndrome (IBS), Crohn's disease, and IBD (inflammatory... Agent:

20130115287 - Intraorally disintegrating tablet: Disclosed is an orally disintegrating tablet which masks bitterness, dissolves well, and which permanently retains good oral disintegration properties immediately following manufacture. The disclosed orally disintegrating tablet is formed by compression-molding an organic acid together with particles comprising active ingredient-containing nuclear particles covered by a layer containing water-insoluble polymers and/or... Agent: Teijin Pharma Limited

20130115288 - Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone: A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to... Agent: Shionogi & Co., Ltd.

20130115289 - Anti-flush compositions: Disclosed are pharmaceutical compositions having a portion of aspirin for intraoral release and another aspirin for gastrointestinal release. The compositions can further include niacin. Methods of using such compositions to treat diseases or conditions suitably treated by niacin are also provided which result in reduced flushing.... Agent: Vitalis LLC

20130115290 - Compositions for the symptomatic relief of stomach pain or gastrooesophageal reflux: Compositions useful for relieving the symptoms commonly known as stomach acidity, heartburn or, more technically, esophageal reflux (GERD), that comprise a fatty acid and a plant extract. These compositions have been tried in patients with clinical records of previous diagnosis of GERD, chronic heartburn, or esophagitis, with a high degree... Agent:

20130115291 - Enteric tablet: The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component.... Agent: Takeda Pharmaceutical Company Limited

20130115292 - Enteric tablet: The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component.... Agent: Takeda Pharmaceutical Company Limited

20130115293 - Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 50 weight percent of a corticosteroid; and about 50 to about 99 weight percent biocompatible polymer.... Agent:

20130115294 - Stable liquid oily ready-to-use formulations, preparation thereof and use thereof: The present invention relates to a stable liquid oily ready-to-use formulation comprising an active pharmaceutical ingredient, which has hydrophobic and/or lipophilic properties and/or which exhibits stability problems in aqueous environments. The present invention further relates to a method for preparing said formulation, and said formulation for use in the medical... Agent: Cts Chemical Industries Ltd.

20130115296 - Methods for treating hepatocellular carcinoma: The present invention provides methods and compositions for treating hepatocellular carcinoma (HCC) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating HCC comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise... Agent:

20130115295 - Rare earth-doped up-conversion nanoparticles for therapeutic and diagnostic applications: This invention provides a composition matter comprising rare earth-doped up-conversion nanoparticles (UCNPs) encapsulated with a silica shell. In one embodiment, a photosensitizer is incorporated into the silica shell. In another embodiment, the composition further comprises a targeting molecule. In still another embodiment, a small interfering RNA (siRNA) molecule is also... Agent:

20130115297 - Stable, durable granules with active agents: A stable, durable granule for feed compositions has a core, at least one active agent; and at least one coating. The active agent of the granule retains at least 50% activity, at least 60% activity, at least 70% activity, at least 80% activity after conditions selected from one or more... Agent: Danisco US Inc.

20130115298 - Extended release compositions comprising as active compound venlafaxine hydrochloride: The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.... Agent: Lycored Bio Ltd.

20130115300 - Ciprofloxacin dry syrup composition: Disclosed herein is a process for preparation of taste masked dry syrup composition of ciprofloxacin comprising Ciprofloxacin taste masked granules along with at least one pharmaceutically acceptable excipient. The present invention also discloses a stable taste masked dry syrup composition of ciprofloxacin.... Agent:

20130115299 - Method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells with microrna145: The present invention provides a method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells comprising delivering miR145 to the cancer or tumor cells, particularly brain tumor and head and neck cancer cells. The invention further provides a pharmaceutical composition comprising miR145 and a... Agent: Taipei Veterans General Hospital

20130115301 - Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt: e

20130115302 - Polysaccharide micro-particle encapsulatin growth factor: A polysaccharide micro-particle encapsulating a growth factor is disclosed and shall include one or more growth factors, and a polysaccharide shell forming a space to encapsulate the growth factor by electrostatic interaction. Also, a method for manufacturing a polysaccharide micro-particle encapsulating a growth factor is disclosed, which shall include the... Agent: Micorna Dermal Therapy Lab Co., Ltd.

20130115303 - Natural treatment for baldness prevention: An all natural formulation for the treatment of baldness in men and women is described. Also described is a method of making the formulation and a method of using it.... Agent: Eden Variety Products, LLC

20130115304 - Compositions and methods for modulating immune response: The present invention relates to a method for modulating immune response in a subject, which comprises administering to the subject an effective amount of a composition comprising a yolk or yolk antibody obtained from an egg of a fowl which has been immunized using Helicobacter pylori as an antigen. In... Agent: Asia Hepato Gene Co.

20130115305 - Microemulsions and its use for preventing airway diseases: The invention relates to novel microemulsions comprising a non-polar lipid, at least one polar solvent, a surfactant, and a polar lipid. A microemulsion of these ingredients provides an environment that substantially encloses airborne particles, and it can be used for entrapping such particles. The inventive microemulsions are especially adapted for... Agent:

20130115306 - Toxin decontaminant food product and method of treating disorders of the gastrointestinal tract: The invention encompasses antidotal food products containing activated charcoal for ingestion into the gastrointestinal tract of a user for treating various gastrointestinal disorders. The antidotal food product is orally administered having the visual appearance and physical properties which enables the desire on the part of young children to chew and... Agent: Denovo Inc.

20130115307 - Method and apparatus for producing a stabilized antimicrobial non-toxic electrolyzed saline solution exhibiting potential as a therapeutic: An improved method and apparatus for producing a stable, non-toxic, antimicrobial electrolyzed saline solution with a broad range of anti-infective and therapeutic applications. The resulting electrolyzed saline solution exhibits a marked lack of toxicity upon intravenous, aspired, oral or topical application in mammals for therapeutic applications providing a broad platform,... Agent:

20130115308 - Doped material: A doped material comprises TiO2 and three non-metal dopants. The first non-metal dopant comprises sulfur, the second non-metal dopant comprises fluorine, and the third non-metal dopant comprises carbon. The sulfur dopant comprises a cationic dopant, the carbon dopant comprises a cationic dopant, and the fluorine dopant comprises an anionic dopant.... Agent:

20130115310 - Compounds useful as inhibitors of atr kinase: d

20130115311 - Compounds useful as inhibitors of atr kinase:

20130115312 - Compounds useful as inhibitors of atr kinase:

20130115313 - Compounds useful as inhibitors of atr kinase:

20130115314 - Compounds useful as inhibitors of atr kinase:

20130115309 - Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells: In one aspect, the invention provides a method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor. In another aspect, the invention provides a method of treating a subject suffering from a tumor comprising myc-driven tumor... Agent: Fred Hutchinson Cancer Research Center

20130115315 - Cosmetic antidandruff composition based on ellagic acid or a derivative thereof and a second, different active compount in a specific weight ratio: The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: (i) one or more compounds selected from ellagic acid, its ethers and the salts of ellagic acid and its ethers, and (ii) one or more compounds selected from pyrithione salts, 1-hydroxy-2-pyridone derivatives and selenium (poly)sulphides, in a... Agent:

20130115316 - Indolealkylamino-withasteroid conjugates and method of use: A group of indolealkylamino-withasteroid conjugates, isolated and purified from Withania somnifera, are described. A synthetic method of making an indolealkylamino-withasteroid compound is provided. In vitro acetyl cholinesterase inhibitory activity and methods for treatment of dementia and dementia-related disorders, such as Alzheimer's disease, and anxiety and depressive disorders in mammals are... Agent: Natreon, Inc.

20130115317 - Method for identifying pre-biotics and compositions containing the same: A method for indentifying test agents that exhibit prebiotic activity on companion animal skin commensal microorganisms and dermatological compositions that include such agents. The method includes providing a test culture of a test agent, a companion animal skin commensal microorganism and a minimal carbon medium. The method provides a time... Agent: The Procter & Gamble Company

20130115318 - Cosmetic composition containing a cypress essential oil complex as an active ingredient for enhancing memory and improving cognitive dysfunction: The present invention relates to a cosmetic composition containing cypress essential oil as a first essential oil and one or more second essential oils selected from the group consisting of pine needle essential oil, lavender essential oil, rosemary essential oil, red thyme essential oil, and bergamot essential oil. The composition... Agent: Skinbio Co.,ltd.

20130115319 - Herbal composition for lowering likelihood of stroke and methods for healing stroke patients: Compositions and methods are provided for lowering blood pressure, lowering blood sugar, lowering cholesterol, prevent stroke, removing age spots, curing stroke, or enlarging blood vessels to remove the toxins from the blood. In one embodiment, the composition comprises the herbal extracts of liquorice root, self-heal, mulberry leaves, chrysanthemum, ginkgo nuts,... Agent:

20130115320 - Therapeutic agent for intranasal administration and method of making and using same: The present invention provides a composition suitable for intranasal administration comprising capsaicin, dihydrocapsaicin, and nordihydrocapsaicin in the form of capsicum used as a therapeutic agent.... Agent: Dynova Laboratories, Inc.

20130115321 - Therapeutic agent for intranasal administration and method of making and using same: The present invention provides a composition suitable for intranasal administration comprising capsaicin, dihydrocapsaicin, and nordihydrocapsaicin in the form of capsicum used as a therapeutic agent.... Agent: Dynova Laboratories, Inc.

20130115322 - Therapeutic compositions and methods for treating cell dysplasia using extracts from raspberry and strawberry: Isolated fruit extracts and components along with a method for treating or preventing a disease or condition by providing a fruit extract fraction having a therapeutically effective amount of activity in modulating undesired signal transduction activity useful for reducing the frequency, duration or severity of a disease or condition in... Agent:

20130108546 - Humanized antibodies that recognize alpha-synuclein: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.... Agent: Neotope Biosciences Limited

20130108547 - Recombinantly produced antibodies targeting erbb signaling molecules and methods of use thereof for the diagnosis and treatment of disease: Compositions and methods useful for the diagnosis and treatment of cancer are provided.... Agent: Fox Chase Cancer Center

20130108548 - Peptide derivatives, preparation and uses thereof: The invention relates to peptide derivatives (peptides and pseudo-peptides) and the use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides of the invention can be used, in particular, to vectorize,... Agent: Centre National De La Recherche Scientifique

20130108550 - Bioabsorbable co-filler for cerebrovascular aneurysms: Materials and Methods for delivering materials for filling aneurysms in which the materials comprise a glycosaminoglycan and optionally, contrast media and physiological buffers and in which delivery methods include percutaneous delivery with a balloon catheter or a needle catheter.... Agent: Abbott Cardiovasculr Systems, Inc.

20130108549 - Peptide probes for diagnostics and therapeutics: Disclosed are agents and methods that may be used to diagnose and treat a variety of diseases associated with conformationally-altered proteins. The agents and methods may be used to identify and deliver drugs useful for treating diseases associated with conformationally-altered proteins.... Agent: Adlyfe, Inc.

20130108551 - Lipid bilayer carrier for drugs or imaging agents: Disclosed are carriers for drugs and/or MR imaging agents having a lipid bilayer shell comprising a phospholipid having two terminal alkyl chains, one being a short chain having a chain length of at most seven carbon atoms, the other being a long chain having a chain length of at least... Agent: Koninklijke Philips Electronics N.v.

20130108552 - Near-ir indocyanine green doped multimodal silica nanoparticles and methods for making the same: The subject invention provides novel fluorescent core-shell nanoparticles comprising an encapsulated fluorescent core comprising an ionically bound fluorescent dye and a metal oxide shell. In one exemplary embodiment of the invention a core containing indocyanine green (ICG) with a silica shell that displays excellent photostability for generation of a near... Agent: University Of Florida Research Foundation Inc.

20130108554 - Contrast agents: The present invention relates generally to multimodal magnetic resonance imaging (MRI) contrast agents. In particular, the present invention provides a MRI contrast agent configured to manipulate both the longitudinal (T1) and transverse (T2) relaxation times of surrounding water proton spins.... Agent: Northwestern University

20130108553 - Metal mixes for use in epicutaneous patch test: A device and method for carrying out epicutaneous patch tests for two or more metal mixes is disclosed.... Agent:

20130108555 - Compositions for visualization of cleaning efficacy and product coverage: The invention relates to cleaning and food processing aide applications whereby unique compositions of GRAS or food additives were developed to assess the effectiveness of cleaning procedures at various stages of the processes and to assess the delivery and adherence of food processing aides. Employing such solutions to clean and/or... Agent:

20130108556 - Pharmaceutical form for combating chemical submission of a medicament: The invention relates to a pharmaceutical form for combating chemical submission, comprising an active ingredient and at least one compound which enables immediate modification of the organoleptic characteristics of a beverage into which the pharmaceutical form is introduced, said compound being selected from the group comprising an opacifier, a fluorescent... Agent: Ethypharm

20130108557 - Cosmetic foam: The present invention provides aerosol foams comprising Aloe vera. In particular, the foams comprise (a) Aloe vera, (b) a surfactant and (c) a propellant. The foams may further comprise one or more of the group consisting of an α-hydroxy acid, a β-hydroxy acid, a humectant, a thickening agent, a dermatologically... Agent:

20130108558 - Formulation comprising nicotine and a cation exchange resin: A method of producing a nicotine delivery product includes preparing a first mixture including nicotine, a cation exchange resin and water by mixing the constituent components of the first mixture. The method optionally includes removing up to 85 wt. % of the water contained in the first mixture to form... Agent: Fertin Pharma A/s

20130108559 - Hydrogen peroxide toothpaste with improved stability: Aqueous oral care compositions containing hydrogen peroxide and having improved stability, such compositions containing at least 35%, by weight of the composition, of water and further including a peroxide compatible abrasive such as fused silica, calcium pyrophosphate and/or dicalcium phosphate, a gel network, and a protection system containing sodium acid... Agent: The Procter & Gamble Company

20130108560 - Chemical treatments for the disruption of dental plaque biofilms and related methods: A thin film composition for oral administration that adheres to and dissolves in a mouth of a user, wherein the thin film is a single layered water-soluble solid comprising at least one D-amino acid contained in a plurality of hydrophobic carriers dispersed throughout the thin film. The hydrophobic carriers comprise... Agent:

20130108561 - Compositions for improving the oral health of animals, methods using the same, and pet treats incorporating the same: Described herein are dental compositions, articles of manufacture including such dental compositions, and methods of using such dental compositions. In some embodiments, the dental compositions include a combination of ascorbic acid with at least one of a hexametaphosphate and a beta glucans. In some instances, the dental compositions are included... Agent: T.f.h. Publications, Inc.

20130108563 - Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds: Pharmaceutical/dermatological emulsions containing at least one avermectin compound, notably ivermectin, include at least one fatty phase and at least one aqueous phase, the at least one avermectin compound being solubilized in the fatty phase, which emulsions are useful for the treatment of a variety of dermatological conditions/afflictions, in particular rosacea.... Agent: Galderma S.a.

20130108564 - Compounds with a skin pigmenting activity and pharmaceutical or cosmetic compositions containing them: R′ is chosen from H, C1-C22 alkyl or alkenyl, aryl or aralkyl, or sugars; and their pharmaceutically acceptable salts, such as sodium, potassium and lysine salts, for use as the active ingredient in pharmaceutical or cosmetic compositions for improving the pigmentation of the human skin, treating pigmentation disorders and/or improve... Agent: Giuliani S.p.a.

20130108562 - Cosmetic composition containing oligopeptides: The invention is directed to the cosmetic use of tetrapeptides according to formula (I) R1-Val-Leu-Leu-Lys-R2 (I) wherein R1 is linked to the NH2-terminal group of the peptide and is chosen from the group consisting of —H, a linear saturated or unsaturated or branched saturated or unsaturated acyl group having 1... Agent: CognisIPManagement Gmbh

20130108565 - Tanning enhancers and self-tanning substances: The invention relates to the use of specific disaccharides and derivatives thereof as self-tanning substance or as tanning enhancer for dihydroxyacetone or for a mixture of self-tanning substances comprising dihydroxyacetone. The invention furthermore relates to the use thereof for the modulation of the hue which is achieved on tanning with... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20130108566 - Skin conditioning compositions containing 12-hydroxystearic acid: Non-solid skin conditioning compositions comprising 12-hydroxy stearic acid, aminosilicone and water are disclosed. The compositions have a relatively low viscosity and are suitable for spreading on the skin.... Agent:

20130108567 - Skin-whitening composition for external application on skin containing extracts from paper mulberry flowers and fruits: The present invention relates to a skin external composition comprising an extract of the flower and fruit of paper mulberry, and more particularly to a skin external composition containing, as an active ingredient, an extract of flower and fruit of paper mulberry, which shows an excellent skin-whitening effect by effectively... Agent: Amorepacific Corporation

20130108568 - Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders: The invention relates to compound of generic formula (I) in which: R1 and R2 represent: OH, a hydrogen atom, a C1-C6 alkyl radical a C1-C6 alkoxy radical, a halogen, or OCOR3; R3 represents: a C1-C24 alkyl radical a C12-C24 alkenyl radical comprising at least one unsaturation; R4 represents: COR5, a... Agent: Pierre Fabre Dermo-cosmetique

20130108569 - Pigment mixture, and use thereof in cosmetics, food and pharmaceuticals: The invention relates to pigment mixtures comprising at least two components A and B. The inventive pigment mixtures are characterized in that component A is embodied as effect pigments while component B is embodied as coloring agents and fillers. Also disclosed is the use of said pigment mixtures in cosmetic... Agent: Merck Patent Gesellschaft

20130108570 - Antiperspirant soft solid compositions comprising a wax blend: An antiperspirant soft solid composition includes a wax blend with glyceryl tribehenate, a first wax additive, and a second wax additive.... Agent: The Procter & Gamble Company

20130108571 - Novel agent for improving the deposition of oil on hair: The use of an agent in a composition intended to be applied to hair is described. The composition can include an oil and a mixture including an amphoteric surfactant and an alkylpolyglucoside to increase a quantity of oil deposited on the hair.... Agent: Rhodia Operations

20130108572 - Cosmetic or dermatological preparation for application on wet skin: An aqueous cosmetic or dermatological preparation for application on wet or moist skin which is substantially emulsifier-free and comprises at least two different polyacrylic acid polymers, at least two different C14-22 fatty alcohols, and at least about 13% by weight of microcrystalline wax, preferably in combination with one or more... Agent: Beiersdorf Ag

20130108573 - Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a... Agent: Lumena Pharmaceuticals, Inc.

20130108574 - Radiopaque, non-biodegradable, water-insoluble iodinated benzyl ethers of poly(vinyl alcohol), preparation method thereof, injectable embolizing compositions containing thereof and use thereof: The invention concerns a radiopaque, non-biodegradable, water-insoluble iodinated benzyl ether of poly(vinyl alcohol) consisting of a PVA having covalently grafted thereon iodinated benzyl groups comprising 1-4 iodine atoms per benzyl group, a process for preparing the same comprising reacting a 0-100% hydrolyzed PVA with a iodinated benzyl derivative comprising 1-4... Agent:

20130108575 - Antibacterial and antifungal peptides: This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.... Agent: C3 Jian, Inc.

20130108576 - Stable antiseptic compositions and methods: Abstract: Provided are methods of improving the stability of antiseptic compositions that include elemental iodine and certain hydroxycarboxylic acids, as well as stable, ready to use antiseptic compositions suitable for use in the nose and anterior nares.... Agent: 3m Innovative Properties Company

20130108577 - Method for preparing an optimum density termite bait composition: A composition in compacted form for use for termite monitoring and control comprises a cellulose material which may be purified cellulose or microcrystalline cellulose as a base bait, the composition being compacted to an optimum density of not less than approximately 1.033 g/cc. Also disclosed is a method for monitoring... Agent: Basf Corporation

20130108578 - Apo-2 ligand variants and uses thereof: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided.... Agent: Genentech, Inc.

20130108580 - Fusion protein and its uses: The present invention relates to a fusion protein comprising a) a first polypeptide selected from among SDF-1 (stromal cell derived factor-1) or peptidase/protease-resistant variants or fragments thereof which have the CXCR4-/CXCR7- binding function of SDF-1; and b) a second polypeptide which is selected from among GPVI (glycoprotein VI), or the... Agent: Eberhard-karls-universitaet Tuebingen Universitaetsklinikum

20130108579 - Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases: Methods for enhancing the suppressive function of myeloid derived suppressor cells (MDSCs) for the treatment of autoimmune diseases using small compounds are disclosed. In certain aspects, the small compounds are glatiramer acetate and mitogen activated protein (MAP) kinase inhibitors. In other aspects, these methods include the administration of exogenous MD-SCs... Agent: Mount Sinai School Of Medicine

20130108581 - Immunocytokines for cancer treatment in combination with chemotherapeutic agents: This invention relates to the treatment of cancer using anti-cancer agents, such as doxorubicin or paclitaxel, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.... Agent: Philogen S.p.a.

20130108583 - Methods of use for cyclopamine analogs: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:... Agent:

20130108582 - Methods of use of cyclopamine analogs: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:... Agent:

20130108584 - Recombinant vector for producing and secreting amino acid sequences of interest by propionibacteria and applications thereof: The present invention relates to a recombinant vector for expressing and secreting, by a propionibacterium, one or more amino acid sequences of interest, wherein said vector comprises at least: under the control of at least one suitable promoter, at least one nucleotide sequence coding for a propionibacteria signal peptide and,... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)

20130108596 - Chondrocyte therapeutic delivery system: Systems and methods for modifying the environment of target cell using genetically altered chondrocytes are provided. The genetically engineered chondrocytes can be used to express a therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes.... Agent: Depuy Mitek,llc

20130108597 - Isolated primate embryonic cells derived from extended blastocysts: An isolated primate embryonic cell is provided as well as cell cultures and cell lines derived therefrom. Also provided are methods of generating and using such cells.... Agent: Technion Research & Development Foundation Ltd.

20130108594 - Method for evaluating angiogenic potential: The invention provides a method for determining the angiogenic signature of a cell or tissue sample and methods for predicting efficacy of angiogenic therapy, for preparing a predictive model for predicting angiogenic potential, for identifying an agent for use in angiotherapy and therapeutic agents and applications.... Agent: Nhs Blood & Transplant

20130108595 - Use of adipose tissue-derived stromal cells in spinal fusion: The present invention encompasses methods and compositions for treating a bone condition. The isolated adipose tissue-derived stromal cell of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications such as in spinal fusion procedures.... Agent: Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

20130108585 - Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition: The present invention relates to conjugated linoleic acid (CLA)-producing strains of probiotic bacteria. In particular, the present invention relates to a selection of bacterial strains belonging to the genus Bifidobacterium which were selected for their ability to produce conjugated linoleic acid (CLA) from linoleic acid (LA). Furthermore, the present invention... Agent:

20130108598 - Method for diagnosing risk of type 1 diabetes and for preventing onset of type 1 diabetes: The invention comprises methods for diagnosing the risk of onset of type 1 diabetes and for preventing the onset of type 1 diabetes. The genetic background, metabolomes, antibodies and diversity of gut microbiota of an individual can be used for diagnosis.... Agent: Teknologian Tutkimuskeskus Vtt

20130108599 - Herbal vaginal compositions: An herbal vaginal composition for treating vaginal infections while maintaining the natural vaginal flora, herbal ingredients comprising: coconut oil as the base ingredient, shea butter, neem oil, lavender oil, vitamin E, lactobacillus, green tea, tea tree, ylang ylang, sweet orange, myrrh, frankincense, nirvanas base, and clove oil.... Agent:

20130108600 - Metabolites in animal feed: The present invention relates to an aquatic animal feed product comprising metabolite derived from probiotic LAB. Hence, such a feed product is highly suitable for use as a feed product for an aquatic animal.... Agent:

20130108601 - Use of chicoric acid and lactic bacterium in food supplement for regulating skin pigmentation: The present invention relates generally to the field of cosmetic and/or food supplement. More specifically, the present invention aims to provide the use of at least an ingredient containing chicoric acid and/or derivatives and a micro-organism and/or an enzyme capable of hydrolyzing chicoric acid and/or derivatives thereof to generate tartaric... Agent: Nestec S.a.

20130108586 - Composition and method of delivery of l-arabinose and select compounds: The disclosure relates to dietary supplement compositions comprising L-arabinose and one or more select compounds, which may include one or more select phytochemical compounds. The claimed compositions are useful in dietary supplements to facilitate mitigating elevated blood sugar levels and managing a user's weight as well as enhancing performance of... Agent:

20130108587 - Methods and compositions for enhancing stem cell mobilization: A method of using fucoidan to enhance stem cell mobilization in a subject, including hematopoietic stem cells (HSCs) and bone marrow stem cells (BMSCs) is provided. In the method, a blended composition of fruits, mushrooms, microorganisms, maternal fluids, and extracts thereof are used to promote trafficking of stem cells, resulting... Agent: Stemtech International, Inc.

20130108593 - Mesenchymal stem cell isolation and transplantation method and system to be used in a clinical setting: A system and method for the percutaneous, autologous transplantation of mesenchymal stem cells and progenitor helper cells (PHC) from bone marrow to degenerated intervertebral discs or joints. This method is designed to be used by operating room staff in a clinical setting to isolate a mesenchymal stem cell population and... Agent: Regenerative Sciences, LLC

20130108590 - Method for producing cell sheet: s

20130108589 - Method of producing neurons from stem cells, the neurons and uses thereof: The present invention belongs to the field of cell transplantation. Particularly, the present invention provides a method of producing neurons for treating injuries with the loss of neuron function from stem cells, wherein the stem cell is a human derived mesenchymal stem cell, preferably human derived placental mesenchymal stem cell,... Agent: Affiliated Hospital Of Ningxia Medical University

20130108591 - Methods for collecting and using placenta cord blood stem cells: An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of... Agent: Cord Blood Science Inc.

20130108588 - Multipotent stem cell cultures: The invention provides methods for propagation of multipotent stem cells from human skin fibroblast samples using an appropriate medium, such as an amniotic fluid medium (AFM), and subsequent differentiation of the cells into cells of any of the three germ layers. The invention also provides methods of differentiating and making... Agent: Saint Peter's College

20130108592 - Use adipose tissue-derived regenerative cells in the modulation of inflammation in the pancreas and in the kidney: Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating inflammation.... Agent: Cytori Therapeutics, Inc.

20130108602 - Methods and uses of nur77 and nur77 agonists to modulate macrophages and monocytes, and treat inflammation, inflammatory disease and cardiovascular disease: Methods of decreasing, reducing, inhibiting, suppressing, limiting or controlling an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation in a subject; decreasing, reducing, inhibiting, suppressing, limiting or controlling an autoimmune response, disorder or disease in a subject; and decreasing, reducing, inhibiting, suppressing, limiting or controlling an adverse... Agent: La Jolla Institute For Allergy And Immunology

20130108603 - Collagen production compound: A topical skin care lotion includes materials for supplementing the production of collagen I and III includes a base of lipophillic or lipophobic material and at least one amino acid. The amino acids are alanine and glycine. Other components of the lotion include iron, vitamin C, manganese, silica and cherry... Agent:

20130108605 - Method of ameliorating oxidative stress and supplementing the diet: wherein R1 is an aromatic backbone and R2 is a sulfur containing ligand. Through formation of disulfide linkages other moieties can be attached to R2 converting the hydrophobic base into a water soluble entity, for ease of delivery, which can be reconverted back to the original compound by biochemical reduction... Agent: The University Of Kentucky Research Foundation

20130108604 - Topical skin care formulations: A topical anti-aging skin care formulation comprising an effective amount of a benzoquinone, such as CoQ10, plus a synergistic pair of stabilizers and a synergistic pair of whiteners. The stabilizers are octyl salicylate and octyl methoxycinnamate. The whiteners are titanium dioxide and zinc oxide. When proper amounts of these ingredients... Agent:

20130108606 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Human Genome Sciences, Inc.

20130108607 - Methods and compositions for treating oxalate-related conditions: The subject invention relates in one aspect to an oxalate degrading composition, which includes at least one oxalate degrading enzyme. The composition includes an enriched insoluble component of fungal biosample, and the composition is effective to degrade oxalate at a pH of 1.9 or higher. The composition is protected from... Agent:

20130108608 - Trna synthetase fragments: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to multi-unit complexes of tRNA synthetase fragments and uses thereof; diverse multi-unit complexes including a tRNA synthetase fragment; compositions and methods for modulating angiogenesis; polynucleotides encoding tRNA synthetase fragments and... Agent:

20130108609 - Transmembrane prostatic acid phosphatase: The present invention relates to a novel transmembrane prostatic acid phosphatase (TM-PAP) protein or the C-terminal part thereof, nucleic acid molecules encoding said protein, vectors containing said nucleic acid molecules and host cells expressing said proteins. The present invention relates also to pharmaceutical compositions containing TM-PAP or the C-terminal part... Agent: Chempath Oy

20130108611 - Fragmented polymeric compositions and methods for their use: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels... Agent: Baxter International Inc.

20130108610 - Inhibition of microbial growth by aconitase inhibition: The present invention is directed to a method of inhibiting aconitase activity of fungal cells in an individual, the method comprising administering an inhibitor of aconitase activity to the fungal cell in an amount effective to inhibit activity of aconitase by said fungal cells.... Agent:

20130108612 - Polynucleotides encoding novel pcsk9 variants: The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the... Agent: Bristol-myers Squibb Company

20130108613 - Amyloid-beta clearance: The present invention relates to a pharmaceutical composition for preventing or treating an amyloid β-caused disease, which comprises as an active ingredient a NIa (nuclear inclusion a) protease or a gene carrier containing a nucleotide sequence encoding the NIa protease. The pharmaceutical composition of this invention is very effective to... Agent: Gwangju Institute Of Science And Technology

20130108614 - Wound healing peptides and methods of use thereof: The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation.... Agent: Tufts University

20130108615 - Date pit composition for the treatment of animals: A method of treating or preventing bacterial infection in an animal comprises administering an effective amount of degraded date pits. Degraded date pits can be produced by the treatment of date pits with fungi.... Agent:

20130108616 - Detection and treatment of lrp4-associated neurotransmission disorders: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also... Agent:

20130108619 - Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods: A method of providing an immunotherapy treatment to a patient includes determining a level of C1 esterase inhibitor or inhibitor activity in the patient, determining an intravenous immunoglobulin dosing protocol for the patient based on the level of C1 esterase inhibitor or inhibitor activity, and administering the immunotherapy treatment to... Agent:

20130108618 - Methods and compositions related to intracellular neutralization by igg: Disclosed are compositions, antibodies, and methods for binding intracellular antigens.... Agent: University Of Maryland

20130108617 - Plasma-derived immunoglobulin for use in the treatment and prevention of immune reconstitution inflammatory syndrome (iris): The present invention relates to plasma-derived immunoglobulin for use in the treatment of immune reconstitution inflammatory syndrome (IRIS). Moreover, the present invention relates to a kit of parts for the treatment of IRIS comprising (a) plasma-derived immunoglobulin; (b) instructions for use to administer plasma-derived immunoglobulin in the treatment of IRIS.... Agent: Universit&#xc4 Tsspital Basel

20130108621 - Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.... Agent:

20130108623 - Antibodies with enhanced or suppressed effector function: Rationally designed antibodies and polypeptides that comprise two Fc region amino acid substitutions that synergistically provide enhanced selectivity and binding affinity to a target Fc receptor are provided. The polypeptides comprise Fc region mutations at two positions that synergistically make the polypeptides more effective when incorporated in antibody therapeutics than... Agent: Zymeworks Inc

20130108626 - Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer: The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more... Agent: F. Hoffmann-la Roche Ag

20130108624 - Cryptic glycan markers and applications thereof: The present invention relates to a novel glycan marker of cancer and monoclonal antibodies against it. Furthermore, novel glycan markers and their use in the detection and monitoring of cancerous cells and cancer-associated or specific antibody signatures are described.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20130108622 - Disulfide stabilized antibodies and fragments thereof: Disulfide Stabilised Antibodies and Fragments Thereof The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, VL and the heavy chain region, VB of the Fab molecule are linked by one or more disulfide bonds, and use of the... Agent: Ucb Pharma S.a.

20130108627 - Humanized pcrv antibody having anti-pseudomonal activity: Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity... Agent: Shionogi & Co., Ltd.

20130108620 - Methods of treatment using anti-erbb antibody-maytansinoid conjugates: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.... Agent: Immunogen Inc.

20130108625 - Treatment of multiple sclerosis (ms): A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favourable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first... Agent: Genzyme Corporation

20130108630 - Amino acyl trna synthetases for modulating inflammation: Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.... Agent:

20130108632 - Etanercept formulations stabilized with amino acids: The invention provides stabilized aqueous pharmaceutical etanercept compositions stabilized with an amino acid and suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.... Agent: Coherus Biosciences, Inc.

20130108634 - Etanercept formulations stabilized with meglumine: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.... Agent: Coherus Biosciences, Inc.

20130108633 - Etanercept formulations stabilized with metal ions: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.... Agent: Coherus Biosciences, Inc.

20130108629 - Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.... Agent: Biogen Idec Hemophilia Inc.

20130108636 - High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins: The invention provides engineered antibody domains (eAds), a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the same. Nucleic acids encoding eAd and/or polypeptide or the fusion protein thereof, as well as compositions or cells comprising the eAd, polypeptide, fusion protein, or nucleic acid also... Agent:

20130108628 - Method for treating cancer pain and/or rescuing analgesic effect of morphine treatment of cancer pain: The present invention provides a method for treating cancer pain by administering to an individual in need of such treatment with a pharmaceutically effective amount of a blocking reagent for ephrinB-EphB signaling. Also provided is a method for reducing opioid tolerance in treating cancer pain thereby rescuing analgesic effect of... Agent:

20130108631 - Methods for detecting antibodies: The present invention relates to methods of detecting Anti-Drug Antibodies. The present invention also relates to methods of monitoring patients undergoing therapeutic antibody treatment. The invention further relates to kits suitable for the implementation of the above methods.... Agent: Theradiag Sa

20130108635 - Methods, compositions, and kits for the treatment of matrix mineralization disorders: The present invention provides methods, compositions, and kits for the treatment of matrix mineralization disorders such as hypophosphatasia. In particular, the present invention provides polypeptides having a soluble alkaline phosphatase fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to patients, e.g., subcutaneously, to treat hypophosphatasia... Agent:

20130108637 - Therapeutic agent for fibromyalgia containing etanercept: Disclosed is a drug effective in the treatment of fibromyalgia. Basically, the disclosed therapeutic agent was created on the basis of experiments showing improvement in symptoms when etanercept was administered to patients suffering from fibromyalgia. Etanercept is known as a therapeutic agent for rheumatoid arthritis, and the JFIQ score of... Agent: Axis Inc.

20130108638 - Antagonist antibodies against ephb3: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.... Agent: Novartis Ag

20130108640 - Antikine antibodies that bind to multiple cc chemokines: An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1α/CCL3, MIP-1β/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.... Agent:

20130108639 - Pharmaceutical composition for preventing or treating cancer: The invention provides a fusion protein comprising (a) a first protein comprising a polypeptide which specifically binds to Annexin A1 and (b) a second protein comprising a polypeptide which induces a cytotoxic activity of a cytotoxic lymphocyte, pharmaceutical compositions comprising the fusion protein, and methods of treating or preventing cancer... Agent: Samsung Electronics Co., Ltd.

20130108641 - Anti-gitr antibodies: The invention provides antibodies that specifically bind to human GITR (hGITR) with high affinity and antagonize the binding of hGITRL to hGITR. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-GITR antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods... Agent: Sanofi

20130108642 - Immunotherapy and diagnosis of mucormycosis using coth: The invention provided Mucorales CotH polypeptides and encoding nucleic acid molecules. The Mucorales CotH polypeptides and encoding nucleic acids can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.... Agent:

20130108643 - Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases: The invention relates to methods of preventing or inhibiting the onset and/or treating autoimmune demyelinating neuropathy and other autoimmune or inflammatory diseases involving macrophage infiltration.... Agent:

20130108647 - Compositions and methods for diagnosis, prognosis and management of malaria: Biomarkers for predicting the severity of malaria and methods for their detection are disclosed. In one aspect, the present application discloses CXCL4, CXCL10, VEGF, PGDF, IL-1Ra, IL-8, MIP-1β, sFas, Fas-L, sTNF-R2, and sTNF-R1 as biomarkers for the severity of malaria. In another aspect, the present application discloses a method for... Agent: Morehouse School Of Medicine

20130108644 - Inhibition of axl signaling in anti-metastatic therapy: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.... Agent:

20130108645 - Methods for enhancing axonal regeneration: The invention provides novel methods of enhancing axonal regeneration. The methods of the invention are suitable for use in treating a subject suffering from a nerve injury.... Agent: The Johns Hopkins University

20130108648 - Nanoparticulate in-situ gels as vitreous humor substitutes for ocular diseases: The present technology provides a nanoparticulate in-situ gelling vitreous substitute, which is a liquid at room temperature to aid easy administration, such as e.g. through a small needle incision, and forms a gel within the eye, which is hydrophilic in nature, similar to the natural vitreous. The vitreous substitute formulation... Agent: Indian Institute Of Technology Bombay

20130108646 - Optimized degenerative muscle disease diagnostics and treatments: Provided herein are optimized methods for treating a degenerative muscle disease, which comprise determining the presence, absence or amount of a biomarker associated with the disease after a drug has been administered, and determining whether a subsequent dose of the drug should be maintained, increased or decreased based on the... Agent: Medimmune, LLC

20130108649 - Modulation of ul24 interactions with protein targets and uses thereof for inhibition of herpesvirus infection: Methods and uses for the treatment of herpesvirus infection based on the inhibition of the interaction between herpesvirus UL24 and non-muscle myosin type IIa (NM2a) are described.... Agent: Institut National De La Recherche Scientifique

20130108650 - Actriib binding agents and uses thereof: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.... Agent: Acceleron Pharma, Inc.

20130108651 - Antibodies to human programmed death receptor pd-1: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.... Agent: Msd Oss B.v.

20130108652 - Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma: The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by D. pteronissinus... Agent: Korea Research Institute Of Bioscience And Biotechnology

20130108653 - Bivalent molecules for hiv entry inhibition: The present invention relates to a new class of virus fusion inhibitors or virus entry inhibitors. More specifically the present invention relates to bivalent molecules that are pre-fusion inhibitors of viruses that makes use of the type (1) fusion mechanism belonging to the groups consisting of Othomyxoviridae, Paramyxoviridae, Retroviridae, Filoviridae... Agent:

20130108654 - Telomerase activity inhibiting peptide and manufacturing method and application thereof: The present invention provides a telomerase activity inhibiting polypeptide. The expression of the polypeptide in tumor cells can inhibit significantly tumor cell telomerase activity, tumor cell growth, and lead to the death of such cells. The present invention further provides a preparation method for the polypeptide and an application thereof... Agent: Shanghai Institutes For Biological Sciences, Cas

20130108657 - Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses: What is described is a novel genetic screen, involving recombinant technology and class I antigen cross-presentation, to search for supraoptimal superagonists of the 27L MART-1 mutant selecting for single amino acid substitution mutants of 27L that activate human antigen-specific CTL clones recognizing the wild-type MART-126-35 epitope. Three novel mutant epitopes... Agent: Fred Hutchinson Cancer Research Center

20130108655 - Cyclic tetrapeptides and therapeutic applications thereof: a

20130108656 - Peptide and method for reducing the phosphate requirement and excretion from farm animals: Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.... Agent: Wisconsin Alumni Research Foundation

20130108658 - Mutated structural protein of a parvovirus: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus, or cell comprising the nucleic acid, a process... Agent: Ludwig-maximilians-universitaet

20130108659 - Protein-based streptococcus pneumoniae vaccine: Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. The vaccines and methods comprise an effective amount of one or more Streptococcus pneumoniae cell wall and/or cell membrane proteins and/or immunogenically-active fragments, derivatives or modifications thereof, wherein the proteins are selected from a... Agent: Ben-gurion University Of The Negev Research And Development Authority

20130108660 - Anti-trypanosome therapeutic and diagnostic applications: The present invention relates to the identification of nucleotide and peptide sequences of a novel HDL transporter located in the flagellar pocket of African trypanosome parasites, and to the use thereof for anti-trypanosomosis diagnostic, therapeutic and vaccine applications in man and in animals.... Agent:

20130108661 - Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells: Provided are methods for inducing an anti-tumor immune response by immunizing a mammal with a composition comprising a tumor cell which expresses a NLR ligand and/or TLR ligand-TAA fusion protein or with an activated DC which has internalized a tumor cell which expresses an NLR- and/or TLR ligand-TAA fusion protein.... Agent: Mount Sinai School Of Medicine

20130108662 - Peptides useful as cell-penetrating peptides: A peptide having an amino acid sequence containing at least eight consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein. The peptide is suitable as a cell-penetrating peptide. A complex of the peptide and a cargo molecule non-covalently bound to the peptide. The cargo molecule... Agent: Evonik Roehm Gmbh

20130108663 - Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination: New methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and the use thereof in cancer vaccination are provided. The method includes introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L,... Agent: Vrije Universiteit Brussel

20130108664 - Cdca5 peptides and vaccines including the same: Isolated peptides derived from SEQ ID NO: 21 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned... Agent: Oncotherapy Science, Inc.

20130108665 - Recombinant tumor vaccine and method of producing such vaccine: The present disclosure provides tumor vaccines useful for preventing and treating tumors and cancers. The tumor vaccines may contain nucleic acids encoding for antigen presenting peptides, cytokines and other factors useful for preventing and treating tumors and cancers, or expression vectors or viruses containing such nucleic acids, or host cells... Agent: Tot Shanghai R&d Center Co., Ltd.

20130108673 - Co-therapy for diabetic conditions: Methods of treating diseases diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a biguanide and a bile acid sequestrant. Drug products including a biguanide and bile acid sequestrants in... Agent: Daiichi Sankyo, Inc.

20130108670 - Compositions and methods for treating full thickness burn injuries: The present invention provides compositions and methods for treating full thickness burn injuries. The present invention provides compositions and methods for promoting healing and regeneration of impaired or damaged tissue at a site of such a full thickness burn injury, as well as promoting vascularization and angiogenesis in regenerating tissue... Agent: Biomimetic Therapeutics, Inc.

20130108669 - Dopaminergic neurons differentiated from pluripotent stem cells and uses of thereof: The present invention provides populations of neural cells derived from pluripotent cells, and methods for making and using the same. Disclosed herein are methods for generating dopaminergic neurons in vitro using a combination of agents that cause differentiation of the pluripotent cells into dopaminergic neurons. Also disclosed are methods for... Agent: The Mclean Hospital Corporation

20130108666 - Glass/carbon nanotube composite material for bone graft support: A composition for bone graft structural support, including a bioglass matrix and a plurality of carbon nanotubes dispersed throughout the bioglass matrix. The carbon nanotubes are generally cylindrical and are substantially between about 10 nanometer and about 20 nanometers in diameter and are substantially between about 5 nanometers and about... Agent:

20130108671 - Hemostatic compositions: The invention discloses a hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis, wherein the composition is present in paste form containing 15.0 to 19.5% (w/w), preferably 16.0 to 19.5% (w/w), 16.5 to 19.5% (w/w), 17.0 to 18.5% (w/w) or 17.5 to 18.5% (w/w), more preferred... Agent: Baxter International Inc.

20130108667 - Method, apparatus and system for electroporation: A method, apparatus and system that employs particles, e.g., nanoparticles, and an electric or electro-magnetic field, to cause electroporation in target cells at reduced fields. Electroporation may be irreversible, leading to targeted cell death, or reversible, allowing species to be introduced into the target cell. The method introduces a particle... Agent:

20130108674 - Ophthalmic compositions for the administration of liposoluble active ingredients: m

20130108675 - Organic compounds: A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.... Agent: Novartis Ag

20130108672 - Pharmaceutical compositions for substituted quinazolinones: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states,... Agent: Resverlogix Corp.

20130108668 - Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.2 to about 20 weight percent of epothilone, e.g. epothilone B; and about 50 to about 99 weight percent biocompatible polymer.... Agent:

20130108677 - Abrasive confectionary products: There is provided a consumable abrasive confectionery product for the reduction of oral malodor and for treatment of other oral cavity conditions, comprising substantially uniformly dispersed abrasive particles configured to at least partially erode deposits in the oral cavity, wherein the abrasive quality of the confectionery product is substantially constant... Agent: Breezy Industries Ltd.

20130108676 - Use of a cellulose fiber: The present invention relates to the use of a cellulose fibre containing incorporated a chitosan and/or chitosan salt and/or having a chitosan and/or chitosan salt on its surface, for the preparation of an article that, when being used, is in contact with the skin of a living mammal with a... Agent: Lenzing Aktiengesellschaft

20130108678 - Ag loaded silica nanoparticle/nanogel formulation, methods of making, and methods of use: Embodiments of the present disclosure, in one aspect, relate to compositions including a silver/silica nanocomposite, methods of making a silver/silica nanocomposite, methods of using a silver/silica nanocomposite, and the like.... Agent:

20130108679 - Personal care composition: According to the invention there is provided a foam or gel personal care composition having a disinfectant action including: 0.03-0.08% w/w of a biocide; a surfactant; a gelling agent; and water.... Agent: The Premiere Polish Company Limited

20130108680 - Implantable tizanidine compositions and methods of treatment thereof: A method of treating the symptoms of spasticity comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of tizanidine to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling... Agent: Endo Pharmaceuticals Solutions Inc

20130108681 - Injectable depot compositions and uses thereof: Injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having a miscibility in water of less than or equal to 7 wt. % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith, a thixotropic agent, and a beneficial agent.... Agent: Durect Corporation

20130108683 - Compositions and methods for treating partial and full thickness wounds and injuries: The present invention provides compositions and methods for treating deep partial thickness or full thickness wounds or injuries. The present invention also provides compositions and methods for promoting healing and regeneration of impaired or damaged tissue at a site of such partial thickness or full thickness wounds or injuries, as... Agent: Biomimetic Therapeutics, Inc.

20130108684 - Hemostatic composition, apparatus, and methods: The present invention provides hemostatic compositions comprising components of the flowers of pharmaceutical chamomile (Chamomilla recutita) and the leaves of dioecious nettle (Urtica dioica). Further inclusion of a biocompatible polymeric base, particularly an alignate, generates a composition with excellent and broad spectrum hemostatic capabilities, with concurrent antiseptic and anti-inflammatory properties.... Agent:

20130108682 - Wound care product comprising a cathelicidin polypeptide: The present invention provides a wound care product comprising a wound care material and a polypeptide having wound care properties. In one embodiment, the wound care material comprises or consists of alginates, amorphous hydrogels, sheet hydrogels, hydrofibres, foams and mixtures thereof. In a further embodiment, the polypeptide having wound care... Agent: Lipopeptide Ab

20130108690 - Anti-apoptotic protein antibodies: Single-domain antibodies that bind pro-apoptotic proteins Bax and caspase-3 are identified and isolated. These single-domain antibodies may be used to modulate the activity of Bax and caspase-3, thereby modulating the symptoms and steps of oxidative stress and/or cell apoptosis, including Bax dimerization, mitochondrial permeabilization and the release of apoptotic proteins.... Agent: National Research Council Of Canada

20130108685 - Cationic lipid: n

20130108692 - Compositions and methods for treating influenza: The present disclosure provides compositions and methods useful for treating influenza. As described herein, provided compositions and methods are based on the development of certain compositions that include an influenza virus hemagglutinin antigen in combination with lipid vesicles that include a non-ionic surfactant (NISVs) and optionally an adjuvant. In certain... Agent: Variation Biotechnologies, Inc.

20130108687 - Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders: Compositions of an inhibitor of a polynucleotide for use in treating or preventing bone disorders such as osteoporosis, osteopenia, bone fracture, bone cancer, as well as impaired bone homeostasis. Preferred compounds to be used in these medical interventions are antagonistic compounds, like nucleic acid molecules, directed against miR-31 and derivatives... Agent: Universitat Fur Bodenkultur Wien

20130108688 - Delivery of h2 antagonists: The present invention provides improved systems and methods for the local delivery of H2 antagonists. The inventive methods include topical administration of an effective amount of a H2 antagonist encapsulated in liposomes. In certain embodiments, the H2 antagonist, for example, Cimetidine, is encapsulated into paucilamellar liposomes, such as NOVASOME® microvesicles.... Agent: Trustees Of Boston University

20130108686 - Method for the delivery of oligonucleotides: The invention relates to a method for obtaining formulations which improve the binding capacity of siRNAs in relation to plasma components, which promote the transport of siRNA in the blood, which increase the passage of siRNA through the cell membrane and, consequently, which increase the inhibitory activity of siRNA. The... Agent: Consejo Superior De Investigaciones Cientificas (csic)

20130108689 - Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs: A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.... Agent: Zomanex, LLC

20130108691 - Microrna as a cancer progression predictor and its use for treating cancer: The present invention is based on the findings that a novel function for miR142-3p in the regulation of Sox2, adenylyl cyclase 9 (AC9), and CD133 expressions, and consequently the overall stemness of recurrent GBM cells as well as CSCs, and that miR142-3p modulated tumor-initiating properties in recurrent GBM. The present... Agent: Taipei Veterans General Hospital

20130108695 - Dosage form: An elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in. gastric fluid, wherein the dosage form is weight biased such that. one end is heavier than the ether end. The dosage form is adapted to float on gastric fluid with its long... Agent: Jagotec Ag

20130108694 - Dry blend formulation of tetrahydrobiopterin: Dry blend powder formulations comprising a pharmaceutical formulation containing tetrahydrobiopterin, and methods of making and using the same, are disclosed herein.... Agent: Biomarin Pharmaceutical Inc.

20130108693 - Dual controlled release dosage form: A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration.... Agent: Osmotica Kereskedelmi Es Szolgaltato Kft

20130108696 - Coated capsules and tablets of a fatty acid oil mixture: Compositions comprising a fatty acid oil mixture and at least one free fatty acid in a coated capsule or a coated tablet form suitable for oral administration, and methods of use thereof, are disclosed. Further disclosed are preconcentrates comprising a fatty acid oil mixture, at least one surfactant, and optionally... Agent:

20130108697 - Modified release dosage form: There is provided a modified release dosage form comprising a core coated with a polymeric coat, said polymeric coat comprising one or more rate controlling polymers, said dosage form having a hole extending through the dosage form resulting in an inner radial surface and an outer radial surface, said core... Agent:

20130108698 - Enteric coated particles containing an active ingredient: Enterically coated particles and chewable tablets made therefrom are disclosed. The enterically coated particles are comprised of a core containing an active ingredient, a first coating layer comprised of polymeric composition having a Tg less than about 40° C. that substantially covers the core; and a second coating layer, which... Agent: Johnson & Johnson Consumer Companies, Inc.

20130108699 - Highly dispersible granulate for the preparation of formulations of high dosage active substances and procedure for obtaining high dosage active substances thereof: By mixing ibuprofen and a disaggregating agent, the invention involves using these components in a proportion ranging between 96% and 97% by weight for ibuprofen, and between 3% and 4% for the disaggregating agent, which may be Sodium croscarmellose, Crospovidone or Sodium carboxymethyl starch, as well as a mixture thereof.... Agent:

20130108700 - Methods and compositions for wound treatment: The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods.... Agent: Halscion, Inc.

20130108702 - Copper/silica nanoparticles, methods of making, and methods of use: Embodiments of the present disclosure, in one aspect, relate to compositions including a copper/silica nanostructure, methods of making a copper/silica nanostructure, methods of using a copper/silica nanostructure, and the like.... Agent:

20130108701 - Solid dosage forms of antipsychotics: The present invention relates to a solid dosage form comprising an antipsychotic, particularly ziprasidone. The present invention also relates to a process for preparation of solid dosage form comprising ziprasidone.... Agent:

20130108703 - Orally disintegrating tablet compositions of lamotrigine: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with... Agent: Aptalis Pharmatech, Inc.

20130108704 - Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and... Agent: Aicuris Gmbh & Co. Kg

20130108705 - Method of making an anti-inflammatory composition: In order to prepare an anti-inflammatory composition extracted from the skin of the Arabian Gulf catfish (Arius bilineatus (Valenciennes)), a gelatinous secretion is collected from the skin of the Arabian Gulf catfish. The gelatinous secretion is biologically active due to the presence of biologically active proteins and lipids. The lipids... Agent: Kuwait University

20130108706 - Dietary formulations: The present invention relates to the field of nutritional support for individuals and reducing the effects of muscle conditions caused by high levels of physical activity. In particular, the invention provides dietary formulations, compositions comprising these formulations and uses of these compositions to support the body's muscle regeneration process.... Agent:

20130108708 - Dental composites comprising nanoparticles of amorphous calcium phosphate: Described herein are dental composites comprising amorphous calcium phosphate nanoparticles and methods of making and using the same. The dental composites display increased Ca and PO4 release, improved mechanical properties, and improved antibacterial properties. Anti-bacterial agents, such as quaternary ammonium salts or silver-containing nanoparticles may be included in the composites.... Agent: University Of Maryland, Baltimore

20130108707 - In situ film-forming bioactive solutions of absorbable multiblock copolymers: An in situ film-forming methyl acetate-based solution of at least one absorbable, segmented block copolymer with amorphous and semi-crystalline segments contains at least one bioactive agent which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane. The solution... Agent:

20130108709 - Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits: Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria... Agent:

20130108710 - Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient: Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.... Agent: Sbi Pharmaceuticals Co., Ltd.

20130108711 - Methods for treating diseases of the lung: Provided herein are methods of treating diseases of the lung in a mammal, including cancer of the lung, mesothelioma, emphysema, and bronchopleural fistula. The methods comprise delivering a biocompatible hydrogel polymer optionally comprising a therapeutic agent directly to a target site using a minimally invasive delivery device, wherein the biocompatible... Agent: Medicus Biosciences, LLC

20130108712 - Agent for cleaning the interiors of shoes: To clean the inside of shoes, a means is proposed in the form of a highly viscous modelling material, consisting of native guar and 75% to 95% by weight combined water and disinfectant with a liquid antiseptic action and aluminium chloride-containing cleaning agents, as well as antimicrobial and anti-fungicidal agents,... Agent: Joker Ag

20130108713 - Composition possessing antioxidant, immonomodulated, and antitumorous action and method of treating neoplasms: A composition produces antioxidant, immunomodulated, and antitumorous effects. The composition includes tannic acid, potassium iodide, and ascorbic acid. The tannic acid, the potassium iodide; and the ascorbic acid preferably are in a weight ratio of 3:1:1. The potassium iodide is preferably in a mole ratio with the tannic acid of... Agent: Ryaoma, Inc.

20130108714 - Method of treating sinusitis, including chronic sinusitis: The present invention relates to a method for treating acute and chronic sinusitis, and in particular, severe chronic sinusitis by exposing affected tissue of the sinus and contiguous tissue in the, nasal cavity and greater oral cavity to effective amounts of chlorine dioxide as a bioactive agent. Compositions and methods... Agent: Sinox Pharma, Inc.

20130108715 - Therapeutic agent and therapeutic device for alleviating ischemia-reperfusion injury: Treatment for alleviating ischemia-reperfusion injury which has minimized risk of side effects and which can suppress neutrophilic infiltration and activation of platelets during ischemia reperfusion comprises administration by inhalation of a mixed gas comprising 21%-98% oxygen, 0.1%-4% hydrogen, 40-80 ppm nitrogen monoxide, and a remainder of inert gas such as... Agent: School Juridical Person Kitasato Institute

20130108717 - Compositions for the treatment of gynaecological disorders: The present invention relates to a combination of a rhatany extract, 18β-glycyrrhetic acid, in free form and in complexes with phospholipids, and Zanthoxylum bungeanum extract, for the topical treatment of gynaecological disorders, especially vulvovaginal infections.... Agent: Indena S.p.a.

20130108718 - Extraction method for providing an organic certifiable stevia rebaudiana extract: A simple extraction method for preparing an organic certifiable stevia extract with high sweetness and optionally with antioxidant properties is provided. The extraction method involves extraction of stevia leaves that have been dried and grinded with a hot solvent generally regarded as safe (GRAS), allowing the dissolution of the sweetening... Agent: Justbio Inc.

20130108716 - Jatropha curcas processing method and products: A process for preparing a food or feed composition from J. curcas is disclosed. The method involves adding an acidified aqueous solution to J. curcas components, to a final pH of between 1 and 5, incubating the acidified mixture for a period for a period of at least 1 hour,... Agent:

20130108719 - Cosmetic and/or pharmaceutical compositions and their applications: Compositions are disclosed containing, as active ingredients, an extract of Allium species, an extract of Citrus species and either an extract of Paullinia species and an extract of Theobroma species, or an extract of Salix species and zinc sulphate, and the method of preparation of these compositions, and cosmetic and/or... Agent: Legacy Healthcare Holding Ltd.

20130108720 - Compositions comprising lipophilic extracts of zingiber officinale and echinacea angustifolia for the prevention and treatment of gastro-oesophageal reflux and chemotherapy-induced emesis: The present invention relates to compositions consisting of a combination of lipophilic extracts of Zingiber officinale and Echinacea angustifolia, obtained by extraction with carbon dioxide under supercritical conditions, which are useful for the prevention and treatment of oesophageal reflux and chemotherapy-induced emesis.... Agent: Indena S.p.a.

20130108721 - Method for preparing raw material for functional foods from barley or wheat seeds: A method is provided for preparing a raw material for functional foods from vernalized, pre-germinated barley or wheat seeds, plumules cultured the vernalized, pre-germinated barley or wheat seeds, or a material resulting from the fermentation of the vernalized, pre-germinated barley or wheat seeds with lactic acid bacteria.... Agent:

20130108722 - Flavored wipe and dispensing system: An example flavored wipe and method of manufacturing the flavored wipe includes a material configured for use as a wipe, and a solution comprising water and a flavoring component. The flavoring component may be stevia or other natural or artificial sweetener. An example dispensing system for the flavored wipe includes... Agent: Taylorbaby, LLC

20130108723 - Use of plants and plant extracts to activate water, alcohol and other liquids: The use of moringa olifera leaves and leaf powder to activate ethanol, alcoholic beverages and water is disclosed. Consumption of the energized liquids can have therapeutic benefits. The activated ethanol can be further used with neutral red dye and ultraviolet (UV) light illumination to indirectly enhance the environmental energy absorption... Agent:

20130108724 - Topical therapeautic composition and palliative treatment method: Disclosed herein is a topical therapeutic composition and method for the palliative treatment of irritated or inflamed perianal tissue. The therapeutic composition comprises olive oil and tea tree oil. The palliative treatment of the invention involves application of the composition to irritated or inflamed perianal tissue. The composition and method... Agent: